Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Regulation of the Cardiovascular System01:27

Regulation of the Cardiovascular System

The regulation of the cardiovascular system allows the body to adapt to various demands and maintain homeostasis.
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intravascular imaging guidance for percutaneous coronary intervention and clinical outcomes: meta-analyses of randomized controlled trials.

Cardiovascular intervention and therapeutics·2026
Same author

Outcomes of Percutaneous and Surgical Interventions of Right-Sided Heart Masses in Older Patients: A Nationwide Comparative Study.

Journal of the American Heart Association·2026
Same author

Multimodality Fusion Imaging of Subclinical Systemic Right Ventricular Remodelling in Congenitally Corrected Transposition of the Great Arteries.

The Canadian journal of cardiology·2026
Same author

Optimal Antithrombotic Therapy for Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis.

Journal of the American Heart Association·2026
Same author

Comment on Carvalho et al.: CT-derived extracellular volume and the prediction target in severe aortic stenosis.

The international journal of cardiovascular imaging·2026
Same author

Myocarditis or coronary artery disease? Diagnostic challenges in patients receiving immune checkpoint inhibitor therapy.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology·2026

Related Experiment Video

Updated: May 31, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

Polycythemia Vera and Cardiovascular Disease: A Mini Review.

Mone Mukai, Tadao Aikawa, Yuya Matsue

    Juntendo Medical Journal
    |May 29, 2026
    PubMed
    Summary

    Polycythemia vera (PV) patients face high cardiovascular risks from thrombosis. While treatments reduce risks, emerging concerns highlight potential cardiotoxicity, necessitating careful monitoring.

    Keywords:
    cardio-oncologycardiotoxicitycardiovascular diseasepolycythemia veraropeginterferon α-2b

    More Related Videos

    Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
    02:47

    Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

    Published on: May 12, 2023

    Related Experiment Videos

    Last Updated: May 31, 2026

    A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
    07:52

    A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

    Published on: November 7, 2017

    Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
    02:47

    Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

    Published on: May 12, 2023

    Area of Science:

    • Hematology
    • Cardiology
    • Oncology

    Background:

    • Polycythemia vera (PV) is a myeloproliferative neoplasm driven by JAK2 mutations.
    • Cardiovascular complications, including thrombosis, are the primary cause of morbidity and mortality in PV patients.
    • Current treatments aim to reduce blood counts and thrombotic risk but may carry cardiovascular toxicity concerns.

    Purpose of the Study:

    • To review the cardiovascular burden associated with Polycythemia vera.
    • To discuss therapeutic strategies for mitigating cardiovascular risk in PV.
    • To explore emerging perspectives on treatment-related cardiotoxicity in PV.

    Main Methods:

    • Literature review of Polycythemia vera, cardiovascular complications, and treatment strategies.
    • Analysis of current therapeutic approaches and their associated cardiovascular risks.
    • Inclusion of recent findings on cardiotoxicity, such as reversible left ventricular dysfunction.

    Main Results:

    • PV significantly increases the risk of arterial and venous thrombosis.
    • Established treatments like phlebotomy, aspirin, and cytoreductive agents improve outcomes but raise cardiotoxicity questions.
    • Ropeginterferon α-2b has been linked to reversible left ventricular dysfunction.

    Conclusions:

    • Managing cardiovascular risk is crucial in Polycythemia vera.
    • Structured monitoring for cardiotoxicity is essential, aligning with cardio-oncology guidelines.
    • Further research is needed to understand and manage treatment-associated cardiovascular toxicity in PV.